Successful treatment association of interleukin-1 inhibitor anakinra and Janus kinase inhibitor baricitinib in Still’s disease

Biotechnological agents such as interleukin-1 (IL-1) IL-6 antagonists have revolutionized the treatment of Still’s disease (1, 2). However, a subset of patients remains challenging to manage, parti...